Electronic Design Automation (EDA) Tools Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2030, Segmented By Product (Computer-aided Engineering (CAE), IC Physical Design & Verification, Printed Circuit Board & Multi-chip Module (PCB & MCM), Semiconductor Intellectual Property (SIP)); By Application (Communication, Consumer Electronics, Automotive, Industrial); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA))
Global Cell and Gene Therapy Drug Delivery Devices Market Size More Than Doubles During Forecast Period to Touch USD 253.7 Thousand by 2029
Global Cell and Gene Therapy Drug Delivery Devices Market is flourishing because of a growing focus on developing efficient therapies and delivery devices for the treatment and management of the increasing prevalence of chronic diseases.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Cell and Gene Therapy Drug Delivery Devices Market size at USD 99.97 thousand in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Global Cell and Gene Therapy Drug Delivery Devices Market size to grow at a significant CAGR of 16.79% reaching a value of USD 253.69 thousand by 2029. Major growth drivers for the Global Cell and Gene Therapy Drug Delivery Devices Market include an increasing prevalence of cancer and chronic diseases, increasing investments in the sector, the imperative to innovate treatments for rare diseases, augmented research and development expenditure in biopharmaceuticals, and a rising number of FDA approvals and clinical trials. Several emerging approaches in cell and gene-based therapies leverage biological engineering to enhance the immune system's ability to combat diseases while preserving the health of surrounding tissues. For instance, antibody-based therapies can enhance the effectiveness of T-cells by intensifying their interactions with cancer cells. Other modifications, such as enhancing the complexity of CAR-T and cancer cell interactions, contribute to refining T-cells' ability to target cancer, thereby reducing harm to normal cells. The escalating aging population, coupled with a growing incidence of cancer cases and genetic disorders globally, is projected to result in a significantly increased demand for drug delivery devices within the cell and gene therapy market. Also, substantial investments by companies in the research and development of cell and gene therapies, along with associated drug delivery devices, underscore the industry's commitment to advancements. The upward trajectory of clinical trials for various genetic and chronic diseases in recent years is poised to propel the cell and gene therapy drug delivery devices market during the forecast period. However, high cost of manufacturing system and lack of standard therapy protocols are anticipated to restrain the overall market growth during the forecast period.
Opportunity - Increasing Investments in Cell Therapy and Gene Therapy R&D
The cell therapy and gene therapy market is witnessing a notable influx of both private and public investment. The appeal of innovative therapies addressing underserved medical conditions has attracted substantial capital through private investments, initial public offerings, and corporate funding. The increasing amount of investments by private players in life sciences R&D is contributing to the rapid growth in funding for cell therapy and gene therapy. Notably, the investment growth rates for gene therapy and cell therapy from 2010 to 2021 are 59% and 63%, respectively, indicating a significant role in advancing the global Cell & Gene Therapy Drug Delivery Devices Market during the forecast period. Additionally, various governments across the regions are actively promoting awareness among patients and healthcare professionals, further fostering the growth of the Global Cell & Gene Therapy Drug Delivery Devices Market.
Impact of Covid-19 on Global Cell and Gene Therapy Drug Delivery Devices Market
Covid-19 pandemic adversely affected the Global Cell and Gene Therapy Drug Delivery Devices Market. Several factors contributed to this exacerbation, including disruptions in manufacturing and logistics processes, leading to significant complexities in the supply chain of materials. The pandemic prompted the suspension of operations at various clinical centers to mitigate the risk of virus exposure. Shipment delays posed challenges for cell therapies with short shelf lives, requiring timely transportation between manufacturing sites and administration centers. Despite these obstacles, market players shifted their focus to addressing pandemic-related challenges, with gene therapy companies actively engaging in Covid-19 vaccine research and manufacturing. This pivot resulted in significant expansions in prices and reimbursements for Competitive Generic Therapy (CGTs).
Global Cell and Gene Therapy Drug Delivery Devices Market – By Commercialized Drugs
Based on commercialized drugs, the Global Cell and Gene Therapy Drug Delivery Devices Market is divided into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis segments. The Luxturna segment holds the highest share in the Global Cell and Gene Therapy Drug Delivery Devices Market by commercialized drugs. Luxturna, represented by voretigene neparvovec-rzyl, is a pioneering gene therapy that directly addresses specific genetic mutations causing retinal dystrophy. It stands out as the first gene therapy approved in the United States for direct administration, focusing on treating confirmed biallelic RPE65 mutation-associated retinal dystrophy. Luxturna's mechanism involves delivering a functional copy of the RPE65 gene directly to retinal cells, utilizing a modified adeno-associated virus as a vector. This innovative approach restores the normal protein production, converting light into electrical signals in the retina and effectively addressing vision loss. Due to its groundbreaking nature and successful outcomes in treating a specific genetic disorder, Luxturna has gained prominence and secured a significant share in the market for cell and gene therapy drug delivery devices.
Global Cell and Gene Therapy Drug Delivery Devices Market – By Region
The in-depth research report on the Global Cell and Gene Therapy Drug Delivery Devices Market covers the market in a number of key countries across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds the highest share in the Global Cell and Gene Therapy Drug Delivery Devices Market. The region's dominance is attributed to the increasing collaborations between various small and medium enterprises and large conglomerates, aiming to develop affordable and high-quality medicines. Also, the rising occurrences of neurodegenerative issues and the growing demand for finding effective treatments for gene disorders through research, diagnostics, and synthetic biology are significant contributors to the regional market's growth. Within the region, the United States is expected to exhibit the fastest market growth in the forecast years. This is attributed to regulatory bodies like the Centre for Biologics Evaluation & Research (CBER) operating in the country, focusing on cell and gene therapy devices. The CBER provides scientific and regulatory guidance to researchers and manufacturers for the development of new products.
Competitive Landscape
Major players operating in the Global Cell and Gene Therapy Drug Delivery Devices Market include Amgen Inc., Bausch & Lomb Incorporated, Renova Therapeutics, Becton, Dickinson and Company, Bluebird bio-Inc., Castle Creek Biosciences, Inc., Helixmith Co. Ltd, Kite Pharma Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., and Pfizer Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Cell and Gene Therapy Drug Delivery Devices Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Cell and Gene Therapy Drug Delivery Devices Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
- 1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
- 2. Executive Summary
- 3. Global Cell and Gene Therapy Drug Delivery Devices Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Increasing prevalence of chronic diseases
- 3.2.1.2. Rising number of clinical trials
- 3.2.2. Restraints
- 3.2.2.1. High cost of manufacturing system
- 3.2.2.2. Lack of standard therapy protocols
- 3.2.3. Opportunities
- 3.2.3.1. Increasing awareness about the devices among patients and doctors
- 3.2.3.2. Rapid growth in investment in cell therapy and gene therapy
- 3.2.4. Challenges
- 3.2.4.1. Shortage of skilled professionals
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter’s Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
- 4. Global Cell and Gene Therapy Drug Delivery Devices Market Overview
- 4.1. Market Size & Forecast, 2019–2029
- 4.1.1. By Value (USD Thousand)
- 4.2. Market Share and Forecast
- 4.2.1. By Product Type
- 4.2.1.1. Subretinal Injection Cannula
- 4.2.1.2. Extension Tube
- 4.2.1.3. Intravenous Catheter
- 4.2.1.4. Sterile Insulin Syringe
- 4.2.1.5. Pre-Filled Syringe
- 4.2.1.6. Infusion Bags
- 4.2.2. By Technology
- 4.2.2.1. Microchip Technology
- 4.2.2.2. Nanotechnology
- 4.2.2.3. Lipid Nanoparticles
- 4.2.3. By Commercialized Drugs
- 4.2.3.1. Luxturna
- 4.2.3.2. Kymriah
- 4.2.3.3. Yescarta
- 4.2.3.4. Zolgensma
- 4.2.3.5. Provenge
- 4.2.3.6. Strimvelis
- 4.2.4. By End User
- 4.2.4.1. Pharmaceuticals & Biotechnology Company
- 4.2.4.2. Academic & Research Institute
- 4.2.4.3. Hospitals & Clinics
- 4.2.5. By Region
- 4.2.5.1. North America
- 4.2.5.2. Europe
- 4.2.5.3. Asia Pacific (APAC)
- 4.2.5.4. Latin America (LATAM)
- 4.2.5.5. Middle East and Africa (MEA)
- 5. North America Cell and Gene Therapy Drug Delivery Devices Market
- 5.1. Market Size & Forecast, 2019–2029
- 5.1.1. By Value (USD Thousand)
- 5.2. Market Share & Forecast
- 5.2.1. By Product Type
- 5.2.2. By Technology
- 5.2.3. By Commercialized Drugs
- 5.2.4. By End User
- 5.2.5. By Country
- 5.2.5.1. United States
- 5.2.5.1.1. By Product Type
- 5.2.5.1.2. By Technology
- 5.2.5.1.3. By Commercialized Drugs
- 5.2.5.1.4. By End User
- 5.2.5.2. Canada
- 5.2.5.2.1. By Product Type
- 5.2.5.2.2. By Technology
- 5.2.5.2.3. By Commercialized Drugs
- 5.2.5.2.4. By End User
- 6. Europe Cell and Gene Therapy Drug Delivery Devices Market
- 6.1. Market Size & Forecast, 2019–2029
- 6.1.1. By Value (USD Thousand)
- 6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Technology
- 6.2.3. By Commercialized Drugs
- 6.2.4. By End User
- 6.2.5. By Country
- 6.2.5.1. Germany
- 6.2.5.1.1. By Product Type
- 6.2.5.1.2. By Technology
- 6.2.5.1.3. By Commercialized Drugs
- 6.2.5.1.4. By End User
- 6.2.5.2. United Kingdom
- 6.2.5.2.1. By Product Type
- 6.2.5.2.2. By Technology
- 6.2.5.2.3. By Commercialized Drugs
- 6.2.5.2.4. By End User
- 6.2.5.3. Italy
- 6.2.5.3.1. By Product Type
- 6.2.5.3.2. By Technology
- 6.2.5.3.3. By Commercialized Drugs
- 6.2.5.3.4. By End User
- 6.2.5.4. France
- 6.2.5.4.1. By Product Type
- 6.2.5.4.2. By Technology
- 6.2.5.4.3. By Commercialized Drugs
- 6.2.5.4.4. By End User
- 6.2.5.5. Spain
- 6.2.5.5.1. By Product Type
- 6.2.5.5.2. By Technology
- 6.2.5.5.3. By Commercialized Drugs
- 6.2.5.5.4. By End User
- 6.2.5.6. Belgium
- 6.2.5.6.1. By Product Type
- 6.2.5.6.2. By Technology
- 6.2.5.6.3. By Commercialized Drugs
- 6.2.5.6.4. By End User
- 6.2.5.7. Russia
- 6.2.5.7.1. By Product Type
- 6.2.5.7.2. By Technology
- 6.2.5.7.3. By Commercialized Drugs
- 6.2.5.7.4. By End User
- 6.2.5.8. The Netherlands
- 6.2.5.8.1. By Product Type
- 6.2.5.8.2. By Technology
- 6.2.5.8.3. By Commercialized Drugs
- 6.2.5.8.4. By End User
- 6.2.5.9. Rest of Europe
- 6.2.5.9.1. By Product Type
- 6.2.5.9.2. By Technology
- 6.2.5.9.3. By Commercialized Drugs
- 6.2.5.9.4. By End User
- 7. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market
- 7.1. Market Size & Forecast, 2019–2029
- 7.1.1. By Value (USD Thousand)
- 7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Technology
- 7.2.3. By Commercialized Drugs
- 7.2.4. By End User
- 7.2.5. By Country
- 7.2.5.1. China
- 7.2.5.1.1. By Product Type
- 7.2.5.1.2. By Technology
- 7.2.5.1.3. By Commercialized Drugs
- 7.2.5.1.4. By End User
- 7.2.5.2. India
- 7.2.5.2.1. By Product Type
- 7.2.5.2.2. By Technology
- 7.2.5.2.3. By Commercialized Drugs
- 7.2.5.2.4. By End User
- 7.2.5.3. Japan
- 7.2.5.3.1. By Product Type
- 7.2.5.3.2. By Technology
- 7.2.5.3.3. By Commercialized Drugs
- 7.2.5.3.4. By End User
- 7.2.5.4. South Korea
- 7.2.5.4.1. By Product Type
- 7.2.5.4.2. By Technology
- 7.2.5.4.3. By Commercialized Drugs
- 7.2.5.4.4. By End User
- 7.2.5.5. Australia & New Zealand
- 7.2.5.5.1. By Product Type
- 7.2.5.5.2. By Technology
- 7.2.5.5.3. By Commercialized Drugs
- 7.2.5.5.4. By End User
- 7.2.5.6. Indonesia
- 7.2.5.6.1. By Product Type
- 7.2.5.6.2. By Technology
- 7.2.5.6.3. By Commercialized Drugs
- 7.2.5.6.4. By End User
- 7.2.5.7. Malaysia
- 7.2.5.7.1. By Product Type
- 7.2.5.7.2. By Technology
- 7.2.5.7.3. By Commercialized Drugs
- 7.2.5.7.4. By End User
- 7.2.5.8. Singapore
- 7.2.5.8.1. By Product Type
- 7.2.5.8.2. By Technology
- 7.2.5.8.3. By Commercialized Drugs
- 7.2.5.8.4. By End User
- 7.2.5.9. Vietnam
- 7.2.5.9.1. By Product Type
- 7.2.5.9.2. By Technology
- 7.2.5.9.3. By Commercialized Drugs
- 7.2.5.9.4. By End User
- 7.2.5.10. Rest of APAC
- 7.2.5.10.1. By Product Type
- 7.2.5.10.2. By Technology
- 7.2.5.10.3. By Commercialized Drugs
- 7.2.5.10.4. By End User
- 8. Latin America Cell and Gene Therapy Drug Delivery Devices Market
- 8.1. Market Size & Forecast, 2019–2029
- 8.1.1. By Value (USD Thousand)
- 8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Technology
- 8.2.3. By Commercialized Drugs
- 8.2.4. By End User
- 8.2.5. By Country
- 8.2.5.1. Brazil
- 8.2.5.1.1. By Product Type
- 8.2.5.1.2. By Technology
- 8.2.5.1.3. By Commercialized Drugs
- 8.2.5.1.4. By End User
- 8.2.5.2. Mexico
- 8.2.5.2.1. By Product Type
- 8.2.5.2.2. By Technology
- 8.2.5.2.3. By Commercialized Drugs
- 8.2.5.2.4. By End User
- 8.2.5.3. Argentina
- 8.2.5.3.1. By Product Type
- 8.2.5.3.2. By Technology
- 8.2.5.3.3. By Commercialized Drugs
- 8.2.5.3.4. By End User
- 8.2.5.4. Peru
- 8.2.5.4.1. By Product Type
- 8.2.5.4.2. By Technology
- 8.2.5.4.3. By Commercialized Drugs
- 8.2.5.4.4. By End User
- 8.2.5.5. Rest of LATAM
- 8.2.5.5.1. By Product Type
- 8.2.5.5.2. By Technology
- 8.2.5.5.3. By Commercialized Drugs
- 8.2.5.5.4. By End User
- 9. Middle East & Africa Cell and Gene Therapy Drug Delivery Devices Market
- 9.1. Market Size & Forecast, 2019–2029
- 9.1.1. By Value (USD Thousand)
- 9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Technology
- 9.2.3. By Commercialized Drugs
- 9.2.4. By End User
- 9.2.5. By Country
- 9.2.5.1. Saudi Arabia
- 9.2.5.1.1. By Product Type
- 9.2.5.1.2. By Technology
- 9.2.5.1.3. By Commercialized Drugs
- 9.2.5.1.4. By End User
- 9.2.5.2. UAE
- 9.2.5.2.1. By Product Type
- 9.2.5.2.2. By Technology
- 9.2.5.2.3. By Commercialized Drugs
- 9.2.5.2.4. By End User
- 9.2.5.3. Qatar
- 9.2.5.3.1. By Product Type
- 9.2.5.3.2. By Technology
- 9.2.5.3.3. By Commercialized Drugs
- 9.2.5.3.4. By End User
- 9.2.5.4. Kuwait
- 9.2.5.4.1. By Product Type
- 9.2.5.4.2. By Technology
- 9.2.5.4.3. By Commercialized Drugs
- 9.2.5.4.4. By End User
- 9.2.5.5. South Africa
- 9.2.5.5.1. By Product Type
- 9.2.5.5.2. By Technology
- 9.2.5.5.3. By Commercialized Drugs
- 9.2.5.5.4. By End User
- 9.2.5.6. Nigeria
- 9.2.5.6.1. By Product Type
- 9.2.5.6.2. By Technology
- 9.2.5.6.3. By Commercialized Drugs
- 9.2.5.6.4. By End User
- 9.2.5.7. Algeria
- 9.2.5.7.1. By Product Type
- 9.2.5.7.2. By Technology
- 9.2.5.7.3. By Commercialized Drugs
- 9.2.5.7.4. By End User
- 9.2.5.8. Rest of MEA
- 9.2.5.8.1. By Product Type
- 9.2.5.8.2. By Technology
- 9.2.5.8.3. By Commercialized Drugs
- 9.2.5.8.4. By End User
- 10. Competitive Landscape
- 10.1. List of Key Players and Their Offerings
- 10.2. Global Cell and Gene Therapy Drug Delivery Devices Market Share Analysis, 2022
- 10.3. Competitive Benchmarking, By Operating Parameters
- 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook